Alterity Therapeutics Ltd
ATH434
Multiple System Atrophy
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on ATH434 for Multiple System Atrophy is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 13h ago
“Pivotal Phase 3 trial activities on track to initiate by year-end 2026”